Lancet Oncology, 1470-2045


  1. 2019
  2. t'Hoen, E., Meyer, S., Durisch, P., Bannenberg, W., Perehudoff, K., Reed, T., & Barber, M. J. (2019). Improving affordability of new Essential Cancer Medicines. Lancet Oncology, 20(8), 1052-1054.
  3. FaMRIsc Study Grp, Saadatmand, S., Geuzinge, H. A., Rutgers, E. J. T., Mann, R. M., van Zuidewijn, D. B. W. D. R., ... Tilanus-Linthorst, M. M. A. (2019). MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. Lancet Oncology, 20(8), 1136-1147.
  4. Krens, S. D., Lassche, G., Jansman, F. G. A., Desar, I. M. E., Lankheet, N. A. G., Burger, D. M., ... van Erp, N. P. (2019). Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution - Authors' reply. Lancet Oncology, 20(6), [e290].
  5. Krens, S. D., Lassche, G., Jansman, F. G. A., Desar, I. M. E., Lankheet, N. A. G., Burger, D. M., ... van Erp, N. P. (2019). Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncology, 20(4), e200-e207.
  6. Bromberg, J. E. C., Issa, S., Bakunina, K., Minnema, M. C., Seute, T., Durian, M., ... Doorduijn, J. K. (2019). Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, 20(2), 216-228.
  7. 2018
  8. 2017
  9. Oudkerk, M., Devaraj, A., Vliegenthart, R., Henzler, T., Prosch, H., Heussel, C. P., ... Field, J. K. (2017). European position statement on lung cancer screening. Lancet Oncology, 18(12), e754-e766.
  10. Lacas, B., Bourhis, J., Overgaard, J., Zhang, Q., Grégoire, V., Nankivell, M., ... MARCH Collaborative Group (2017). Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncology, 18(9), 1221-1237.
  11. Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., ... RECIST Working Grp (2017). iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncology, 18(3), E143-E152.
  12. 2016
  13. Reijneveld, J. C., Taphoorn, M. J. B., Coens, C., Bromberg, J. E. C., Mason, W. P., Hoang-Xuan, K., ... Baumert, B. G. (2016). Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, 17(11), 1533-1542.
  14. Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., ... Stupp, R. (2016). Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, 17(11), 1521-1532.
  15. 2015
  16. Alexander, S., Pole, J. D., Gibson, P., Lee, M., Hesser, T., Chi, S. N., ... Int Pediat Oncology Mortality Clas (2015). Classification of treatment-related mortality in children with cancer: A systematic assessment. Lancet Oncology, 16(16), E604-E610.
  17. Shapiro, J., Van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., ... CROSS Study Grp (2015). Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncology, 16(9), 1090-1098.
  18. Rubin, G., Berendsen, A., Crawford, S. M., Dommett, R., Earle, C., Emery, J., ... Zimmermann, C. (2015). The expanding role of primary care in cancer control. Lancet Oncology, 16(12), 1231-1272.
  19. Lin, N. U., Lee, E. Q., Aoyama, H., Barani, I. J., Barboriak, D. P., Baumert, B. G., ... Response Assessment Neuro-Oncology (2015). Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncology, 16(6), E270-E278.
  20. 2014
  21. Horeweg, N., Scholten, E. T., de Jong, P. A., van der Aalst, C. M., Weenink, C., Lammers, J-W. J., ... de Koning, H. J. (2014). Detection of lung cancer through low-dose CT screening (NELSON): a prespecifi ed analysis of screening test performance and interval cancers. Lancet Oncology, 15(12), 1342-1350.
  22. Larkin, J., Del Vecchio, M., Ascierto, P. A., Krajsova, I., Schachter, J., Neyns, B., ... Blank, C. U. (2014). Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncology, 15(4), 436-444.
  23. 2013
  24. 2012
  25. Woll, P. J., Reichardt, P., Le Cesne, A., Bonvalot, S., Azzarelli, A., Hoekstra, H. J., ... NCIC Clinical Trials Grp Sarcoma D (2012). Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncology, 13(10), 1045-1054.
  26. 2011
  27. van Gijn, W., Marijnen, C. A. M., Nagtegaal, I. D., Kranenbarg, E. M-K., Putter, H., Wiggers, T., ... Dutch Colorectal Canc Grp (2011). Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncology, 12(6), 575-582.
  28. van Hooft, J. E., Bemelman, W. A., Oldenburg, B., Marinelli, A. W., Holzik, M. F. L., Grubben, M. J., ... Collaborative Dutch Stent-In Study (2011). Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial. Lancet Oncology, 12(4), 344-352.
  29. Kempers, M. J. E., Kuiper, R. P., Ockeloen, C. W., Chappuis, P. O., Hutter, P., Rahner, N., ... Ligtenberg, M. J. L. (2011). Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncology, 12(1), 49-55.
Previous 1 2 Next

ID: 1566534